Therapeutic focus area We develop a novel technology for an unmet medical need
We are keen in our commitment to bring the best solution to patients globally. We are constantly developing a technology to address serious wound conditions. We concentrate our efforts on a core set of wound therapeutic areas, where we have already proven the safety and efficacy, and where we feel we can have an even greater impact on wound care and how it is managed.
About wound care
Wound care is an ever-evolving medical device industry that prospers due to its considerable product innovation. Companies are constantly striving to create products that are easier for physicians to use, that fight infection, and that take less time for wound closure. Due to these factors, this market is expected to increase in value over the coming years.
The largest competitors in this field were almost able to collectively capture the majority of the global $US35 billion wound care market in 2018. Products are offered at a variety of price points with diverse device portfolios. Diversification and product bundling are expected to have significant impact on the industry competition in the near future. Reimbursement is also likely to have a large impact on this market as products sold for off-label uses may soon be no longer eligible for reimbursement. Unfortunately, NO drugs, specifically topical pharmaceuticals are available in this market at this time.
As leading experts in wound healing and therapies, we focus on treatments that will improve the standard of care for chronic wounds. Skin wounds in healthy individuals usually heal quite quickly on their own. Nonetheless, a chronic wound is a wound that does not heal in a predictable amount of time like most wounds do in healthy individuals. They close very slowly, keep on opening up, or don't heal at all. People who develop chronic wounds often have an underlying condition that causes even minor pressure to lead to wounds that then no longer heal. The main factors that are involved include circulation problems, venous insufficiency, inflammatory diseases and diabetes. Poorly healing wounds are more common on the feet or lower legs. Doctors consider wounds that do not heal within three months to be chronic. These wounds cause patients severe emotional and physical stress and create a significant financial burden on patients and the whole healthcare system. Treatment for chronic wounds often takes a long time and can be painful. In addition to good wound care that include debridement, cleansing, offloading and control of infection of the wound, and wound coverage with dressings, it's important to treat the underlying condition that contributed to the development of the chronic wound. In addition to good wound care some doctors use technical methods to help chronic wounds to heal faster including smart dressings, hyperbaric oxygen therapy, vacuum-assisted closure (VAC therapy), ultrasound therapy, electromagnetic therapy and Skin grafts.
We fight diabetic foot ulcer...
The diabetic foot ulcer problem is one of the most disabling complications of diabetes and is associated with poor quality of life and, lower-limb amputation and premature mortality. The incidence of diabetes has nearly quadrupled in the past three decades, and the number of diabetic patients has risen to over 420 million among the world’s adult population, and this number is predicted to reach 640 million by 2040. Within the diabetic population, nearly 25% of all diabetic patients have or will develop diabetic foot ulcers during their lifetime making diabetic foot ulcer to become epidemic.
Globally, diabetic foot ulcers are now associated with an astonishing direct annual cost of care reaching US$30 billion including hospitalization, management of wounds and infections, and minor and major amputations. Direct medical costs associated with diabetic foot ulcers present additional considerable indirect economic loss to patients, their families and society through lost income, disability, decreased societal contributions and mortality.
Diabetic foot ulcers are typically categorized as neuropathic, ischaemic, or neuroischaemic ulcers. Of the three types, the most severe adverse outcomes occur with an ischaemic diabetic foot ulcers, because healing time, ulcer recurrence, risk of amputation, and mortality are the largest. The incidence of hospitalization of diabetic patients with a foot ulcer is high because of infection and many of these patients require a limb amputation. Moreover, 55% of patients with diabetic foot ulcers who had a lower extremity amputation will require a subsequent amputation within three years. The risk for mortality of a diabetic patient with a foot ulcer is 2.5 times higher than that of a diabetic patient without a foot ulcer. In addition, up to 70% of patients may die within five years after amputation.
Risk factors for a diabetic foot ulcer can be divided to three groups: pathophysiologic variations, anatomic deformities, and trauma. Pathophysiologic variations happen at the molecular level leading to complications comprising peripheral vascular disease, peripheral neuropathy, a compromised immune system, and defective wound healing. Neuroarthropathy contributes to foot deformity, leading to high plantar pressures and increased risk of skin rupture. These risk factors do not classically occur independently, but rather in combination, further increasing the risk of ulceration. Finally, external influences, such as acute or lasting trauma, are often the originating factors in the development of diabetic foot ulcers.
Development of a diabetic foot ulcer is also exacerbated by defective wound healing due to poor blood flow to the foot and depletion of growth factors and cytokines, which delays its healing and closure. Diabetic foot ulcers have an extended inflammatory phase with impaired neovascularization and fibroblast dysfunction and are characterized by degradation of the extracellular matrix and impeded formation of the provisional matrix that initiate the wound healing repair process.
The management of diabetic foot ulcers is multidisciplinary. The existing guidelines for managing a diabetic foot ulcer include standard-of-care treatment which comprises blood glucose control, treatment of comorbidities, local wound care with efficient debridement, cleansing, control of infection, offloading, vascular evaluation, and revascularization if required, the use of wound dressing types that maintain a moist environment, and increasing patient's awareness to prevention and treatments. In addition, the intricate challenges of the ulcer environment, including ischaemia, hypoxia, oxidative stress, microbial infection, as well as the role played by inflammatory cells have to be considered. Unfortunately, the outcomes are usually unsatisfactory when using these management strategies. Therefore, there is a need to complement the standard-of-care treatment with therapies that promote skin regeneration, accelerate wound healing, restore skin function, and maintain the efficacy of any applied or administered drug in the diabetic foot ulcer environment.
Within the sharp increase in the incidence of diabetes seen in the last four decades, and the complex and costly management of the recurrent ulcers in diabetic patients, diabetic foot ulcer creates a significant societal and health challenge. Moreover, failure to provide a significant safe and effective therapy for healing of foot ulcers, the diabetic foot ulcer problem is further exacerbated. Therefore, an effective solution has become tremendously needed for the debilitating diabetic foot ulcer problem